QSQi Su

Qi Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qi Su has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Baosheng Wang

    Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China

    1 shared publication
  • Hongzhuan Yin

    Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China

    1 shared publication
  • Liliang Hao

    Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China

    1 shared publication
  • Shanshan Song

    Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China

    1 shared publication
  • Shaolong Sun

    Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China

    1 shared publication
  • Tao He

    Department of Clinical Pharmacology, College of Pharmacy, China Medical University, No. 77 Puhe Street, Shenbei District, Shenyang, 110004, Liaoning, China

    1 shared publication

Latest Publications

  • Expression and clinical significance of SALL4 and β-catenin in colorectal cancer

    by Liliang Hao, Yan Zhao, Zhen Wang, Hongzhuan Yin, Xin Zhang, Tao He, Shanshan Song, Shaolong Sun, Baosheng Wang, Zhijie Li, et al.

    Previous studies on the expression of Sal-like 4 (SALL4), a zinc finger transcription factor, had conflicting results in colorectal cancer (CRC). The main aim of this study was to investigate the expression of SALL4 and its relationship with β-catenin in CRC. Immunohistochemistry was performed to examine the expression of SALL4 and β-catenin in a cohort of 149 patients with CRC, 12 with atypical hyperplasia, 25 with benign tumor and 38 with normal tissue. Expression patterns of SALL4 and β-catenin and correlation with clinicopathological features were investigated. The relationship between SALL4 and β-catenin was examined by immunofluorescence and co-immunoprecipitation using CRC cell lines, SW480, SW620, HCT116 and HT29. Immunohistochemical analysis revealed significantly lower expression of SALL4 in CRC (46.3 %) than atypical hyperplasia (68.0 %, p < 0.05) and normal tissue (78.9 %, p < 0.01). Well-differentiated CRC seemed to express more SALL4 (47.6 %) than moderately (45.8 %) and poorly-differentiated cancers (18.8 %) (p < 0.05). However, SALL4 expression positively correlated with lymph node metastasis and tumor-node-metastasis (TNM) and Dukes stages (all p < 0.05) suggesting a new mechanism involved in the function of SALL4 in CRC. β-catenin was expressed significantly higher in CRC (69.1 %) than normal tissue (21.1 %, p < 0.01), and positively correlated with CA19-9 level in serum (p < 0.05). SALL4 and β-catenin were positively correlated in CRC (Spearman correlation coefficient R = 0.536, p < 0.01). The group of co-expression of the two molecules showed advanced lymph node metastasis, TNM stage and Dukes stage (all p < 0.05). Double-labeling immunofluorescence and co-immunoprecipitation indicated that SALL4 and β-catenin co-localized in the nucleus and cytoplasm and interacted. Taken together, our results revealed that SALL4 and β-catenin were positively correlated in CRC. In CRC cells, SALL4 and β-catenin co-localized and interacted. The function of SALL4 in promoting lymph node metastasis and advanced clinical stage might partly be due to the interaction with β-catenin.